A novel therapy in microvascular obstruction in ST-elevation myocardial infarction: pressure-controlled intermittent coronary sinus occlusion therapy

Future Cardiol. 2023 Sep;19(12):615-623. doi: 10.2217/fca-2023-0002. Epub 2023 Nov 7.

Abstract

Percutaneous coronary intervention has transformed the management of ST-elevation myocardial infarction (STEMI) due to a reduction in early mortality and need for repeat revascularization. However, the conventional revascularization strategy, combined with state-of-the-art anti-thrombotic and antiplatelet therapies, can still be associated with poor clinical outcome in some patients, because of reperfusion injury and microvascular obstruction contributing to the infarct size. To address this important therapeutic need, a broad-range of device-based treatments have been introduced. This is an overview of the pressure-controlled intermittent coronary sinus occlusion (PiCSO) device (Miracor Medical SA) which has been proposed for STEMI patients. PiCSO therapy could lead to an improved perfusion, decrease microvascular dysfunction, and thus potentially reduce infarct size.

Keywords: PiCSO; STEMI; ischemia; primary percutaneous intervention; reperfusion injury.

Publication types

  • Review

MeSH terms

  • Coronary Circulation
  • Coronary Sinus*
  • Heart
  • Humans
  • Microcirculation
  • Percutaneous Coronary Intervention* / adverse effects
  • ST Elevation Myocardial Infarction* / complications
  • ST Elevation Myocardial Infarction* / therapy
  • Treatment Outcome